Heron Therapeutics: Impending Catalysts Makes It A Must Watch!
Heron Therapeutics, Inc. (NASDAQ: HRTX) has a major upcoming catalyst in the form of the upcoming Prescription Drug User Fee Act (PDUFA) date for FDA approval on May 12, 2021 for HDX-011 (Zynrelef). HTX-011 is an extended-release, dual-acting local anesthetic that uses a combination of...
